Rivaroxaban for 18 Months vs 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)
Circulation 2024 Nov 18;[EPub Ahead of Print], Y Yamashita, T Morimoto, N Muraoka, W Shioyama, R Chatani, T Shibata, Y Nishimoto, Y Ogihara, K Doi, M Oi, T Shiga, D Sueta, K Kim, Y Tanabe, N Koitabashi, T Takada, S Ikeda, H Nakagawa, K Tsukahara, M Shoji, J Sakamoto, S Hisatake, Y Ogino, M Fujita, N Nakanishi, T Dohke, S Hiramori, R Nawada, K Kaneda, K Ono, T KimuraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.